Share on StockTwits

Tetraphase Pharmaceuticals (NASDAQ:TTPH) Insider Guy Macdonald sold 15,000 shares of the stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $9.00, for a total value of $135,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

A number of research firms have recently commented on TTPH. Analysts at Brean Capital initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Thursday, April 3rd. They set a “buy” rating and a $23.00 price target on the stock. Analysts at Needham & Company LLC raised their price target on shares of Tetraphase Pharmaceuticals from $15.00 to $17.00 in a research note on Thursday, March 6th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Tetraphase Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $18.83.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded up 1.62% during mid-day trading on Wednesday, hitting $9.43. The stock had a trading volume of 121,772 shares. Tetraphase Pharmaceuticals has a 52-week low of $7.02 and a 52-week high of $17.74. The stock’s 50-day moving average is $10.03 and its 200-day moving average is $12.29. The company’s market cap is $243.6 million.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.53) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.45) by $0.08. The company had revenue of $2.50 million for the quarter, compared to the consensus estimate of $2.97 million. Analysts expect that Tetraphase Pharmaceuticals will post $-2.07 EPS for the current fiscal year.

Tetraphase Pharmaceuticals, Inc, incorporated on July 7, 2006, is a clinical stage biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.